Rheinmetall's Execution Test: Two Brokers Cut to €900 as the Backlog Meets Its Moment of Truth

Two of Europe's most closely watched brokerages have arrived at the same €900 price target for Rheinmetall from opposite directions — and the convergence says less about the number than about what investors are now being asked to believe.

Bank of America Securities stripped the defence contractor of its "Buy" rating on Monday, moving to "Neutral" and slashing its target from €1,300. A day earlier, Berenberg had trimmed its own target from €1,020 to €900 while keeping a "Hold" stance. Analyst George McWhirter expects Rheinmetall to cut its 2030 revenue goal by 14% when the company holds its Capital Markets Day on 26 November.

The trigger for both moves is the same: weaker growth prospects for armoured vehicles and artillery ammunition, tied to delays and acceptance problems on existing contracts.

What the company actually told the market

Rheinmetall's own numbers, released roughly a week ago, frame the debate. The order backlog stood at €78.0 billion at the end of September. Revenue for the first nine months of 2026 came in at €8.4 billion, with operating profit of €1.34 billion and an operating margin of 16.0%.

The guidance cut that followed is where the trouble sits. Full-year 2026 revenue is now expected at around €13.2 billion, down from a prior range of €13.7–14.2 billion. The projected operating margin was trimmed to roughly 18.5% from about 19%. Management pointed to the likely delay in awarding the Arminius Boxer contract and to postponed lot acceptances for artillery ammunition.

Both explanations point at a single variable: timing. The question for shareholders is whether expected business actually lands — and when.

Why the market is fixated on execution

A cheaper valuation case rests on the company converting deferred orders and acceptances into revenue, not on the promise of fresh bookings. Anyone betting on a rebound needs confidence in delivery on what is already contracted; anyone staying cautious can lean on the already-lowered full-year targets.

That makes the margin line as important as the top line. A recovery would carry more conviction if revenue recognition and profitability improved together. Berenberg's decision fits the cautious reading — a lower target with an unchanged rating sets a restrained valuation frame.

The constructive counterargument has an operating base: nine-month revenue of €8,376 million and operating profit of €1,339 million show the business is still growing. That case would gain force if Rheinmetall catches up on the delayed acceptances and the postponed order firms up, allowing the guidance cut to be read as a timing issue rather than a structural one.

A Belgian order and an insider purchase

Longer-range demand is not in question. Belgium has ordered 20 Skyranger 30 systems, a contract worth a mid-three-digit million euro amount, with deliveries due to begin at the end of 2028. The order offers a longer view of the business, and its weight in the valuation should grow if Rheinmetall simultaneously contains the near-term execution problems.

CEO Armin Papperger added a confidence signal of his own on Thursday, buying shares via Xetra worth an aggregate €502,484.40. That gesture carries more weight if operating developments back up his optimism.

The risk that skepticism hardens

The serious bear case combines deferred business with a lower margin forecast. If further acceptances slip or orders take longer to materialise, uncertainty over the timing of the business could persist, forcing investors to re-examine how durable the expected revenue and earnings trajectory really is. Strong demand would help less in that scenario as long as execution lags.

The decisive line runs between limited slippage and persistent delivery problems. Additional delays would raise the risk of further guidance adjustments.

What to watch on 26–27 November

Rheinmetall's Capital Markets Day, scheduled for 26 and 27 November 2026, is the next concrete checkpoint. Comments on the timing of the business and the durability of earnings targets will matter most. A positive impulse is plausible if management credibly categorises the delays and substantiates its outlook; if execution stays murky, a cautious valuation will keep its arguments. Investors should anchor their view on how concretely the company describes the path from expected orders and acceptances to revenue and profit.